Table 1.
Clinical characteristics of the study population
| AC EGFR+ (n = 54) | AC EGFR- (n = 54) | SCC (n = 54) | p-value | ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| AC EGFR+ vs. AC EGFR- | AC EGFR- vs. SCC | SCC vs. AC EGFR+ | |||||
| Age, yr | 64.9 ± 9.3 | 64.2 ± 9.2 | 66.7 ± 9.4 | 0.358 | |||
| Male gender, n (%) | 28 (51.9%) | 25 (46.3%) | 52 (96.3%) | < 0.001 | 0.564 | < 0.001 | < 0.001 |
| Body mass index (kg/m2) | 25.0 ± 2.5 | 25.0 ± 3.4 | 24.7 ± 3.0 | 0.882 | |||
| Smoking status | |||||||
| Non-smoker, n (%) | 30 (55.6%) | 31 (57.4%) | 3 (5.6%) | < 0.001 | 0.846 | < 0.001 | < 0.001 |
| Ever smoker, n (%) | 24 (44.4%) | 23 (42.6%) | 51 (94.4%) | ||||
| Pack-years, median (IQR) | 0 (0-30) | 0 (0-27) | 39 (20-46) | < 0.001 | 0.671 | < 0.001 | < 0.001 |
| Stage, n (%) | |||||||
| I-II | 41 (75.9%) | 44 (81.5%) | 45 (83.3%) | 0.603 | |||
| III-IV | 13 (24.1%) | 10 (18.5%) | 9 (16.7%) | ||||
| Nodal stage | |||||||
| N0 | 39 (72.2%) | 45 (83.3%) | 39 (72.2%) | 0.296 | |||
| N1-2 | 15 (27.8%) | 9 (16.7%) | 15 (27.8%) | ||||
| Follow-up duration months, median (IQR) | 27.5 (24.0-29.0) | 22.0 (18.8-25.3) | 25.0 (11.8-27.0) | < 0.001 | < 0.001 | 0.193 | 0.004 |
| Recurrence, n (%) | 16 (29.6%) | 13 (24.1%) | 9 (16.7%) | 0.280 | |||
| Death, n (%) | 2 (3.7%) | 1 (1.9%) | 6 (11.1%) | 0.085 | |||